Applicant, as named in the Orange Book

Alkermes Inc

Alkermes plc · Nasdaq: ALKS

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Aristada on 6 Apr 2039. 4 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Aristada NDA 207533 · 4 strengths aripiprazole lauroxil	aripiprazole lauroxil	6 Apr 2039 patent, carve-out possible	patent, carve-out possible
Aristada Initio Kit NDA 209830 aripiprazole lauroxil	aripiprazole lauroxil	6 Apr 2039 patent, carve-out possible	patent, carve-out possible
Lybalvi NDA 213378 · 4 strengths olanzapine; samidorphan l-malate	olanzapine; samidorphan l-malate	12 Nov 2041 patent	patent
Lumryz NDA 214755 · 4 strengths sodium oxybate	sodium oxybate	16 Mar 2042 patent, carve-out possible	patent, carve-out possible

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.